Known Medicine said it is building the world's largest purpose-built 3-dimensional cell culture dataset with millions of images of patient cancer cells responding to hundreds of drugs and combinations.
Their machine learning-based analysis relies on high-content images of these 3D micro-tumors to better understand why cells respond to one treatment over another.
Functional outcomes are combined with high dimensional -omics datasets to identify the best patients for existing drugs, and the best new drug candidates.
Their ability to capture patient-to-patient variability allows us to narrow the drug discovery funnel to identify a best-in-class molecule.
Additionally, they were recently recognized by VentureBeat, who named Known Medicine as the recipient of their AI Innovators award. This award spotlights a startup that holds great promise for making an impact with its AI innovation.
The BioTech Breakthrough Awards program aims to perform the most comprehensive evaluation of life sciences and biotechnology tools, services and companies TODAY, with nominations coming in from the best and brightest biotechnology innovators around the world.
All award nominations are fully analyzed, evaluated and scored by our expert panel of judges, representing a mix of technical, business, academic and marketing expertise within the industry. The evaluation criteria for the BioTech Breakthrough Awards program are focused around the concept of innovation.
Based in Salt Lake City, UT, Known Medicine is building a predictive engine that captures patient-to-patient variability to develop the best drug for every cancer.
Known Medicine merges cancer biology and machine learning to understand drug efficacy and patient-specific predictors of response.
By understanding how and why a patient responds to which therapy, Known Medicine said it is able to develop effective drug treatments with a high likelihood of success, and discover new drugs as its engine grows.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval